Abbott Laboratories (NYSE:ABT) stock fell on Thursday after the company revised its 2026 earnings outlook below expectations.
Earnings Beat Fails To Offset Weak 2026 Outlook
The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion.
Abbott reported adjusted earnings of $1.15 per share, beating the Wall Street estimate of $1.14 and management guidance of $1.12-$1.18 per share.
Sales increased 7.8% on a reported basis, and 3.7% on a comparable basis (includes Exact Sciences).
Medical Devices And Diabetes Care Drive Growth
Medical Devices sales increased 13.2% on a reported basis to $5.54 billion and 8.5% on a comparable basis.
Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management.
In Diabetes Care, with sales of around $2.08 billion, sales of continuous glucose monitors grew 14.2% on a reported basis and 7.6% on a comparable basis.
…